Company Overview and News

 
BIGBEN INTERACTIVE : TENNIS WORLD TOUR: MISE EN PLACE DE 500 000 EXEMPLAIRES

21h globenewswire
Communiqué de presse Lesquin, 22 mai 2018 19h30 Tennis World Tour ® MISE EN PLACE DE 500 000 EXEMPLAIRES

 
BIGBEN INTERACTIVE : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

2018-05-09 globenewswire
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

 
BIGBEN INTERACTIVE : Annual sales for FY 2017/18 up by 17.9% at 245.4 M€

2018-04-23 globenewswire
Over FY 2017/2018 (ended March 31) Bigben Interactive achieved a turnover of 245.4 M€ up 17.9% compared to the previous year. The Group thus reached the top of the range for its annual sales target initially set at 245 M€

 
BIGBEN INTERACTIVE : Hausse de 17,9% du chiffre d'affaires 2017/18 À 245,4 M€

2018-04-23 globenewswire
Bigben a réalisé pour son exercice 2017/18 (clôturé au 31 mars 2018), un chiffre d'affaires de 245,4 M€, en progression de 17,9%. Le Groupe se positionne ainsi au sommet de la fourchette de son objectif d'activité fixé initialement à 245 M€.

 
BIGBEN INTERACTIVE : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

2018-04-11 globenewswire
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

 
BIGBEN INTERACTIVE informe ses actionnaires de son éligibilité au PEA-PME

2018-03-27 globenewswire
Sur la base des comptes annuels consolidés 2016/2017, Bigben Interactive répond aux critères établis par le Ministère de L'Economie (décret d'application n°2014-283 en date du 4 mars 2014). En conséquence, les actions Bigben Interactive peuvent être inclues au sein du PEA-PME.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...